Cargando…

Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy

The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Huan, Chen, Ze-Tan, Zhu, Xiao-Dong, Li, Ling, Qu, Song, Wei, Zhao, Su, Fang, Wei, Jing-Ni, Liang, Zhong-Guo, Mo, Qi-Yan, Wu, Jiang-Bo, Meng, Hui-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/ https://www.ncbi.nlm.nih.gov/pubmed/28968954 http://dx.doi.org/10.18632/oncotarget.16399

Ejemplares similares

Downregulation of CD166 inhibits invasion, migration, and EMT in the radio-resistant human nasopharyngeal carcinoma cell line CNE-2R
por: Sun, Yongchu, et al.
Publicado: (2019)

ALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer
por: Tachezy, Michael, et al.
Publicado: (2012)

Effects of intensity-modulated radiotherapy and chemoradiotherapy on attention in patients with nasopharyngeal cancer
por: Wei, Qing, et al.
Publicado: (2017)

Expression and Role of CD166 in the Chronic Kidney Disease
por: Sun, Yan, et al.
Publicado: (2015)

Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy
por: Zhang, Guangying, et al.
Publicado: (2019)

ANGI-03 Functional roles of CD166/activated leukocyte cell adhesion molecule (CD166/ALCAM) for glioblastoma invasion
por: Kijima, Noriyuki, et al.
Publicado: (2020)

Prognostic Value of CD166 Expression in Cancers of the Digestive System: A Systematic Review and Meta-Analysis
por: Ni, Chao, et al.
Publicado: (2013)

ALCAM/CD166 Is Involved in the Binding and Uptake of Cancer-Derived Extracellular Vesicles
por: Cardeñes, Beatriz, et al.
Publicado: (2022)

Identification of non-invasive biomarkers for predicting the radiosensitivity of nasopharyngeal carcinoma from serum microRNAs
por: Li, Kaiguo, et al.
Publicado: (2020)

Recommendations for Updating T and N Staging Systems for Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
por: Liang, Zhong-Guo, et al.
Publicado: (2016)

Biological characteristics of CD133(+) cells in nasopharyngeal carcinoma
por: ZHUANG, HUI-WEN, et al.
Publicado: (2013)

Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis
por: Han, Susu, et al.
Publicado: (2017)

Bertillón 166
por: Soler Puig, José, 1916-
Publicado: (1960)

Bertillón 166
por: Soler Puig, José
Publicado: (1960)

Bertillón 166
por: Soler Puig, José, 1916-
Publicado: (1987)

Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction
por: Chappell, Paul E., et al.
Publicado: (2015)

Association of CD166 expression with clinicopathologic characteristics of colorectal cancer
por: Moslemi, Dariush, et al.
Publicado: (2016)

Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer
por: Tan, Fang, et al.
Publicado: (2014)

Oboensonate Opus 166 = Oboe sonata op. 166
por: Saint-Saëns, Camille, 1835-1921
Publicado: (2010)

Radiomics for Diagnosis and Radiotherapy of Nasopharyngeal Carcinoma
por: Zhang, Yu-mei, et al.
Publicado: (2022)

Contribution of age at diagnosis to cancer-specific survival of nasopharyngeal carcinoma patients receiving radiotherapy
por: Zhang, Wei-Ming, et al.
Publicado: (2023)

Higher N stage and serum ferritin, but lower serum albumin levels are associated with distant metastasis and poor survival in patients with nasopharyngeal carcinoma following intensity-modulated radiotherapy
por: Chen, Xiaoqian, et al.
Publicado: (2017)

CD166 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma
por: Andisheh-Tadbir, Azadeh, et al.
Publicado: (2016)

IAU Colloquium No. 166
por: Breitschwerdt, Dieter, et al.
Publicado: (1998)

Memorandum: experiment S166
por: Brückner, W
Publicado: (1981)

S166. Submission Withdrawn
Publicado: (2018)

Identification of CALM as the potential serum biomarker for predicting the recurrence of nasopharyngeal carcinoma using a mass spectrometry-based comparative proteomic approach
por: Meng, Huiling, et al.
Publicado: (2017)

Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy
por: Pan, Xin-Bin, et al.
Publicado: (2020)

ALCAM (CD166) as a gene expression marker for human mesenchymal stromal cell characterisation
por: Brinkhof, Bas, et al.
Publicado: (2020)

Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2017)

Etiology and management of nasopharyngeal hemorrhage after radiotherapy for nasopharyngeal carcinoma
por: Zhan, Jiabin, et al.
Publicado: (2019)

Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas
por: Wang, Fuyu, et al.
Publicado: (2014)

Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
por: Donizy, Piotr, et al.
Publicado: (2015)

CD166-specific CAR-T cells potently target colorectal cancer cells
por: He, Shuai, et al.
Publicado: (2022)

Intensity-modulated radiotherapy controls nasopharyngeal carcinoma distant metastasis and improves survival of patients
por: Chen, Xiaoqian, et al.
Publicado: (2016)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

The clinical characteristics of secondary primary tumors in patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy: A retrospective analysis
por: Zhao, Wei, et al.
Publicado: (2016)

Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
por: WU, PING, et al.
Publicado: (2011)

Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma
por: Li, Xiao-Yu, et al.
Publicado: (2019)

166th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_suc05c65qsaatdf40vknfot63n